AU4576293A - A major histocompatibility complex antigen for use as vaccine against an immunodeficiency virus - Google Patents
A major histocompatibility complex antigen for use as vaccine against an immunodeficiency virusInfo
- Publication number
- AU4576293A AU4576293A AU45762/93A AU4576293A AU4576293A AU 4576293 A AU4576293 A AU 4576293A AU 45762/93 A AU45762/93 A AU 45762/93A AU 4576293 A AU4576293 A AU 4576293A AU 4576293 A AU4576293 A AU 4576293A
- Authority
- AU
- Australia
- Prior art keywords
- antigen
- cells
- class
- human
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title claims description 38
- 108091007433 antigens Proteins 0.000 title claims description 38
- 102000036639 antigens Human genes 0.000 title claims description 38
- 241000700605 Viruses Species 0.000 title claims description 30
- 206010061598 Immunodeficiency Diseases 0.000 title claims description 12
- 208000029462 Immunodeficiency disease Diseases 0.000 title claims description 12
- 230000007813 immunodeficiency Effects 0.000 title claims description 12
- 229960005486 vaccine Drugs 0.000 title claims description 12
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title description 5
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 17
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 10
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 5
- 102000043129 MHC class I family Human genes 0.000 claims description 4
- 108091054437 MHC class I family Proteins 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 3
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 102000006390 HLA-B Antigens Human genes 0.000 claims 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 description 69
- 210000004027 cell Anatomy 0.000 description 52
- 241000713311 Simian immunodeficiency virus Species 0.000 description 20
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000004224 protection Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000009696 proliferative response Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108700005089 MHC Class I Genes Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000000521 hyperimmunizing effect Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010073443 Ribi adjuvant Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229940124718 AIDS vaccine Drugs 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000010910 CD28 Antigens Human genes 0.000 description 1
- 108010062433 CD28 Antigens Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010014691 Lithostathine Proteins 0.000 description 1
- 102100027361 Lithostathine-1-alpha Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 229910001679 gibbsite Inorganic materials 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- -1 propylene glycol Chemical compound 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
A MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN FOR USE AS
VACCINE AGAINST AN IMMUNODEFICIENCY VIRUS
- 1 -
VACCINES This invention relates to vaccines against immunodeficiency viruses.
Cyno olgus macaques vaccinated with either inactivated partially purified simian immunodeficiency virus (SIV) , fixed SIV-infected C8166 (a human T lymphoblastoid cell line) cells or fixed uninfected C8166 cells can be protected against a challenge infection with the 32H isolate of SIVmac 251 (grown in C8166)1'2. Protection is correlated with the levels of antibody response to cellular antigens in the human cells from which the virus immunogen was grown 2"6. However, the mechanism of protection is unclear.
We have analyzed sera from these monkeys. We have found that there is positive correlation of protection with antibody response to the HLA class I molecule. Furthermore, sera from protected monkeys inhibited xenoantigen but not alloantigen-induced monkey T cell proliferation in vitro and the inhibition could be blocked by adsorption with murine P815 cells transfected with human HLA class I genes.
Accordingly, the invention provides a major histocompatibility complex (MHC) class I antigen for use in a method of treatment of the human or animal body by therapy, in particular for use as a vaccine against an immunodeficiency virus.
The invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable rcarrier or diluent and, as active ingredient, a MHC class I antigen. The invention further provides use of a MHC class
I antigen in the manufacture of a medicament for use as a vaccine against an immunodeficiency virus.
The antigen is preferably a human class I antigen. The class I molecule may therefore be HLA-A, HLA- B or HLA-C or /32-microglobulin (02m) which is the 0-chain of the HLA class I molecule. The antigen may be the entire
class I molecule in which the heavy chain is HLA-A, HLA-B or HLA-C. These are known antigens and can be obtained in purified form. They may be prepared as recombinant proteins. Alternatively, the class I antigen may be given presented by transfected cells, i.e. by cells transfected with a gene encoding the antigen and which consequently express the antigen. Transfected cells which may be administered to a human may be transfected cells of a human diploid cell line. Such cell lines have been tested for safety for the purpose of human vaccine manufacture. An appropriate cell line is the MRC5 cell line.
Allogenic lymphocytes which present a class I antigen may be administered to a patient. The lymphocytes may be given as live cells, for example as a blood transfusion. Alternatively they may also be given as fixed or inactivated cells. The lymphocytes may be ones in which the expression of the class I antigen has been enhanced, for example by stimulation with a mitogen or gamma- interferon.
The antigen may be used to vaccinate a host against an immunodeficiency virus. The host may be a human or animal but typically it will be wished to vaccinate a human against a human immunodeficiency virus (HIV) . That virus may be HIV-1 or HIV-2. A prophylactic treatment for disease states attributable to infection by an immunodeficiency virus can therefore be provided. The class I antigen may in particular act as an AIDS vaccine. An effective amount of the antigen is administered to a host it is wished to vaccinate. The antigen can be given parenterally, for example subcutaneously or intramuscularly. The amount of antigen per dose depends on a variety of factors such as the age and the condition of the subject involved. A parenteral dose typically consists of from 20 μg to 1 mg of antigen, for example from 50 to 500 μg of antigen. A number of
doses may be given, for example from 2 to 4 doses over a period of up to six months. Each dose may be given one or two months apart.
An agent for use as a vaccine against an immunodeficiency virus is therefore provided. A pharmaceutical composition also comprising a pharmaceutically acceptable carrier or diluent can be formulated. The composition is thus sterile and pyrogen- free. The composition may also comprise an adjuvant such as Al(OH)3 or saponin.
Compositions for intramuscular or subcutaneous injections may contain together with the antigen a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
The MHC class I antigens can be safely used by virtue of their negligible toxicity.
The following Examples illustrate the invention. In the accompanying drawings: Figures la - d show the results of radioimmunoprecipitation followed by SDS-PAGE, and
Figure le shows the result of flow cytometry analysis.
Example 1 1. Monkeys were vaccinated as follows: 1179-
182, 4 x 500 μg formalin-fixed SIVmac 251 (32H isolate; 11/88 pool) + SAF-1 adjuvant subcutaneously (sc) ; J134-137, 3 x 500 μg formalin-fixed SIV mac 251 + RIBI adjuvant36, sc; J138-141, 4 x 100 μg formalin-fixed SIVmac 251 + RIBI, sc; 1217-220 and J68-71, 4 and 2 doses respectively of 2 x 106 SIVmac 25-1 infected C8166 cells fixed with glutaraldehyde + Quil-A adjuvant, sc; J72-75, 2 doses of 2 x 106 C8166 cells fixed with glutaraldehyde + Quil-A adjuvant, sc. All the animals were challenged intravenously with ten 50% monkey infectious doses (MID50) SIVmac 32H isolate, 11/88 pool (grown in C8166 cells) 1
week after the final boost.
With the exception of monkeys J68-70, J72 and J73, the protected animals were not given a booster vaccination before rechallenge with the same preparation of virus stock. Protection was determined using the previously described method of polymerase chain reaction (PCR) for SIVmac proviral DNA with σaσ. pol as primers7 as well as by virus isolation using direct cocultivation of monkey peripheral blood mononuclear cells (PBMC) with C8166 cells. Virus was detected by the appearance of cytopathic effects (CPE) and confirmed by immunfluorescence of virus antigen on infected cells using standard methods. Cultures which did not show CPE were maintained for at least 28 days before being discarded as negative. a-d, Actively dividing C8166 cells (20-30 x lO6) were labelled for 6 hr with 0.5mCi 35S-methionine in ethionine-free RPMI medium containing 10% foetal calf serum (FCS) , lysed and radioim une precipitated as previously described8. The washed immune complexes were reduced and electrophoresed in a 12.5% acrylamide gel. Gels were treated with Amplify (Amersham) , dried and exposed to Kodak X-Omat RP film at -70°C. e, One hundred μl of a suspension of 1 x 10° P815 or P815 cells transfected with human HLA class I molecules B27 (P815-B27) per ml in RPMI 1640 containing 10% FCS were incubated with 100 μl of serial 4 fold dilutions (1/30 - 1/7680) of monkey plasma (from day of challenge) containing 0.1% sodium azide for 30 min at 4"C. The cells were washed thrice in RPMI with 10% FCS and sodium azide before a further 30 min incubation with 100 μl of 1:100 of rabbit antibody to human immunoglobulin conjugated to FITC (DAKO) . The cells were washed as before and resuspended in PBS containing 1% formaldehyde. The percentage and peak channel fluorescence were analyzed on a FACS Consort 30 (Becton Dickinson) . The end-point titre was taken as the dilution where 20% of the cells were positive.
The results are shown in Figure 1. Figures la to le show that sera from protected monkeys contain antibodies specific for human HLA class I molecule. a, 35S-methionine labelled C8166 cell lysates were immune precipitated with prebleed (B) and hyperimmune (A) plasma (20μl) from monkeys vaccinated with inactivated purified SIVmac (1179, 1180, 1181, 1182), fixed SIV infected C8166 cells (1217, 1219, J68, J69, J71) or C8166 cells (J73, J75) . With the exception of J71, J75 and 1219, all the other monkeys were protected against SIVmac 251 (grown in C8166 cells) challenge infection. b, In tracks 1181 + W6/32 and anti-02m + 1182', the radiolabelled lysate was pre-precipitated twice with plasma from 1181 or anti-32m before subsequent precipitation with mAb W6/32 (specific for a monomorphic determinant on human MHC class I molecule HLA-A, -B, -C) or 1182 plasma respectively. c, Similarly, in track 1181 + OKT11, precipitation with mAb 0KT11 was subsequent to that with 1181 plasma. 1181 PB denotes pre-immune plasma. d, 35S-methionine labelled cell lysates of a Herpes papio transformed monkey B lymphoblastoid cell line were immune precipitated with 25μl prebleed or hyperimmune plasma from protected monkey 1181 and 2μl (ascites fluid) of. mAb W6/32 or L243 (specific for nonpolymorphic determinants of human class II molecule HLA-DR) . e, FACS analysis of anti-human HLA class I reactivity by prebleed and hyperimmune plasma from a representative monkey, 1181, using mouse P815 cells transfected with HLA B27. Results similar to b-e were obtained with sera from other protected monkeys. 2. Detection of Cellular Antigens on SIV and HIV-1 virions bv enzvme-1inked immunosorbent assay fELISA)
The 32H cognate isolate of SIVmac 251 and the HIV-1 isolate GB8 were grown in C8166 cells and partially purified by gel exclusion chromatography to minimise loss
of envelope glycoprotein9. Both virus preparations were inactivated with formalin and dialysed into phosphate- buffered saline (PBS) before use. For the ELISA assay, 50μl of SIVmac (2μg/ml) or HIV-1 (16μg/ml) diluted in 0.1M carbonate buffer pH 9.6 were added to each well of a 96 well microtitre plate (Nunc, Maxi Sorb) and all subsequent steps carried out as previously described10.
Monoclonal antibodies (mAbs) and rabbit antibody to human immunoglobulin conjugated to horse radish peroxidase (1:100, DAKO) were diluted in PBS containing
0.05% Tween 20 and 10% heat-inactivated New Born Calf serum (HI NCS) . Dilutions of mAb used were 1:100 for ascites • fluid, 20-50μg/ml for purified immunoglobulin and neat spent tissue culture supernatant. All washes were with PBS containing 0.05% Tween 20. The substrate used was 2,2'- Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (SIGMA) and the optical density (O.D.) was measured at 405nm.
The results are shown in Table 1. Values (mean + 1 SEM, N=6) that were five times higher than the negative control reading were considered as positive (in bold type) . The mAbs used were obtained from the AIDS directed programme, MRC (ADP373, ADP317, ADP318, ADP336, ADP351, ADP356, ADP359) ; the American Type Tissue Culture Collection (W6/32, L203, L227, L243, OKT3) ; Bristol-Myers Squibb, Seattle (9.3) and OKTll and nm3l were kind gifts from Dr. D. Cantrell, ICRF, Lincoln's Inn Field, London and Prof. A. McMichael, Institute for Molecular Medicine, Oxford respectively. All the mAb used have been checked
for activity using flow cytometry (data not shown) Table 1.
3. Inhibition Xenoantiσen-driven Monkey T Cell Proliferation bv Sera from Protected Monkevs
Monkey PBMC were isolated from defibrinated blood (obtained from monkeys vaccinated with SIV env) by centrifugation on percoll gradients. PBMC at 1 x 106 per ml RPMI 1640 containing 10% autologous serum and 2- mercaptoethanol (5 x 10"5M) were dispensed at lOOμl/well
into a 96 well flat-bottomed plate (Costar) .
Then 50μl of the indicated dilutions of sera (all heat inactivated at 56°C for 45 min) from protected (P) or not protected (NP) monkey or medium were added to the wells. This was followed by the addition of 50μl of SIV gpl40 (Repligen, 5μg/ml) . In the mixed lymphocyte cultures, 50μl containing 1 x 105 irradiated C8166 cells (7500 R) or PBMC from a naive monkey J7 (2500 R) were added as stimulating antigen. The cultures were incubated at 37°C in a humidified C02 incubator for 5 days and were pulsed with lμCi/well 3H-thymidine (Amersha , specific activity 25Ci/mmol) during the final 6 hr of incubation. Cultures in triplicates were harvested on an automatic cell harvester (LKB, Sweden) and radioactivity counted in a β counter (LKB, Betaplate, Sweden) . In the adsorption experiments, 700μl of 1:40 diluted monkey sera were incubated with 107 P815 or P815- Al cells followed by a second incubation with 107 P815 or P815-B27 cells respectively.
The preabsorbed sera were filtered (0.22μm) and appropriately diluted before adding to the cultures. The results are shown in Table 2. Each value represents mean + 1 SEM, N=3. Those values showing >75% inhibition are indicated in bold type. Similar results were also obtained with other sera and monkey PBMC.
4. Inhibition of PHA. OKT3 or Antiσen-driven Human T Cell Proliferation bv Sera from Protected Monkeys
Human PBMC were isolated from defibrinated blood (obtained from an individual vaccinated 4 times with botulinum toxoid) by centrifugation on Histopaque (SIGMA) gradients. The assay for T cell proliferation is essentially the same as in Table 2 except that Phytohaemagglutinin (PHA, Wellcome Diagnostics, llμg/ml) or botulinum toxoid (obtained from Dr. D. Sesardic, 2.5μg/ml) or purified OKT3 (5ng/ml) were used to stimulate the T cells. Ascites fluid of mAbs W6/32 and ADP 314 (anti-HIV-1 p55/p24) were also used as control antibodies. The cultures were incubated for 3 days in the case of cultures with PHA or OKT3 and 5 days with antigen. The results are shown in Table 3. Each value represents mean + 1 SEM, N=3. Those values showing >75% inhibition are indicated in bold type. Similar results were also obtained with other monkey sera. Control monkey J142 was vaccinated with RIBI adjuvant only.
Table 3
5. Discussion
Radioim une precipitation of 35S-methionine labelled C8166 cell lysate with the monkey sera demonstrate that all the sera from protected but not from unprotected monkeys recognise two major protein bands, 12 and 44kDa (Fig. la) . These bands were precipitated by sera from all the protected animals in the three vaccine groups but not by their preim une sera. Blocking experiments were carried out with 35S-methionine labelled C8166 cell lysate by pre- precipitation with serum from protected monkeys followed by precipitation with mAb W6/32 (specific for a monomorphic determinant on human MHC class I molecule HLA-A, - B, -C) . Alternatively, the lysate was pre-precipitated with rabbit anti-32m (the β chain of HLA class I molecule) followed by precipitation with serum from protected monkeys.
Results shown in Fig. lb demonstrate that the 12 and the 44kDa bands are 32m and the heavy (h) chain of HLA class I molecule respectively. Flow cytometry analysis also shows that sera from protected monkeys recognised a murine cell line (P815) transfected with human HLA class I B27 (Fig le) ; mean antibody titre of protected monkeys was log10 3.1 ± 0.13 (N=32) , and of the unprotected group was 1.86 + 0.09 (N=ll) , P< 0.0005. The intensity and mass of the bands around the 44 Da region precipitated by sera from some protected monkeys (Fig. la) suggest that other T cell surface proteins with similar molecular weights such as CD28 (44kDa) , CD2 (Til, 50kDa) and actin (44kDa) may also be recognised.
However, the sera from protected monkeys vaccinated with purified SIVmac 251 virus do not contain anti-CD2 (Fig. lc) or anti-CD28 antibodies (data not shown) . The sera from protected monkeys did not precipitate the α-chain or the 0-chain of the class I molecule of 35S-methionine labelled. Herpes papio-transformed monkey B lymphoblastoid cell lines (Fig. Id) , suggesting that the anti-human class I antibodies in the sera are directed at polymorphic
regions of the human HLA class I molecule.
The high levels of anti-human HLA class I antibody induced in protected monkeys vaccinated with purified SIVmac 251 virus suggest that the purified virus preparation may contain HLA class I antigen. Our ELISA results (Table 1) confirm that the partially purified SIVmac 251 virus preparation used for immunisation, and a HIV vaccine preparation (GB8) , contain a HLA class I molecule and, additionally, CD3, a T cell antigen forming part of the T cell receptor (TcR) complex, but little or no detectable class II, CD4, CD2 or CD28 antigens. However, sera from protected monkeys were not able to precipitate' any bands depicting the CD3 γ-, δ- , e-, ξ-, and η- chains (26, 20 and 16kDa) , (Fig. la) indicating that CD3 was poorly immunogenic in these monkeys that the level of anti- CD3, if present is below the limit of our assay system.
Several reports have shown that mAb to HLA class I heavy chain or to 32m can inhibit T cell proliferation and activation in vitro11"19. In addition, these antibodies are able to inhibit HIV replication in vitro20*22. We investigated the effect of sera from protected and unprotected monkeys on the proliferative response of peripheral blood T cells from monkeys to irradiated C8166 cells or monkey PMBC or a recombinant SIV antigen (rgpl40) in vitro (Table 2) . Sera from unprotected monkeys had no effect on any of the proliferative responses. Although sera from protected monkeys had no effect on the proliferative responses to irradiated monkey cells or rgpl40, they were strongly inhibitory to the proliferative response of monkey T cells to C8166 cells. The inhibitory effect of the sera was significantly removed by adsorption with P815 cells transfected with human HLA class I genes
(Al and B27) but not with P815 cells alone (Table 2) .
We also investigated the effect of the sera from protected monkeys on the proliferative responses of human peripheral blood T cells to phytohaemagglutinin (PHA) ,
anti-CD3 antibody (OK3) and a specific antigen, botulinum toxoid (BTxd) (Table 3) . Sera from unprotected monkeys had no effect on the antigen-specific proliferation, and only a weak inhibitory effect (J139) , vaccinated with SIV) on OKT3-driven response at high concentrations. In contrast, sera from protected monkeys and the mAb W6/32 strongly inhibited all these response. The inhibitory effects of these sera were again removed by adsorption with P815 cells transfected with human HLA class I genes (Al and B27) (data not shown) .
Our results demonstrate a direct correlation between antibody response to HLA class I antigen and protection of monkeys from SIVmac 251 (grown in C8166 cells) infection. The precise mechanism of the possible protection by this antibody is at present unclear. It may be that the antibody reacts with the class I antigens in the virus envelope and thereby blocks the interaction of gpl20 with the CD4 determinants on the target cells by steric hindrance. However, this seems unlikely since sera from protected monkeys did not block the binding of live SIV to CD4-bearing human T cells23.
Furthermore, sera of unprotected monkeys contain high levels of specific anti-SIV antibody s^6.23-24 indicating that blocking virus-CD4 interaction alone may not be a major protective mechanism in the present system. The presence of high levels of SIV-specific antibody in unprotected monkeys also argues against the notion that cross reaction between class I antigens and lentivirus may play an important role in protection against SIV infection25.
However, it does not rule out the possibility that specific neutralising antibody could protect monkeys against a homologous challenge infection with cloned SIV26. It is also unlikely that anti-CD4 antibody plays a significant role in the present system since no anti-CD4 antibody was detected in the sera of protected monkeys by
flow cytometry (data not shown) , nor is CD4 antigen present in the SIV virus preparation (Table 1) . In contrast to a previous report27, we failed to detect class II antigens in our SIV virus preparation. This may be due to the different procedures used in purifying the viruses.
Our data suggest that the anti-class I antibody may contribute towards the protection against SIV infection by down-regulating T cell activation, which is known to be required for HIV replication 2β"3**. This is consistent with previous reports that anti-class I antibody can prevent HIV replication in human PMBC20"22. The precise mechanism by which anti-class I antibodies down regulate T cell activation is unknown. They may act by inhibiting monocyte antigen presentation. Therefore when protected monkeys were challenged with SIV preparations containing human class I antigens, the anti-human class I antibody could bind and effectively block these antigens from reacting with the monkey antigen presenting cells, thereby preventing the dominating xenogenic activation (>10x higher than anti-SIV response. Table 2) of T cells and hence inhibiting virus replication.
Since the anti-human class I antibody does not cross- react with the monkey class I antigens (Fig. Id) , it would not block the monkey class I antigens (present in SIV grown in. monkey cells) from binding to the monkey antigen presenting cells (Table 2) when the vaccinated monkeys were challenged with that virus. Thus there is no down- regulation of allogenic activation and so virus replication is not inhibited. This may explain the finding that vaccinated monkeys were not protected against challenge infection with SIV grown in monkey cells ">"6.
Another way by which anti-class I antibody can down- regulate T cell activation is by acting directly on the class I molecules on T cells 19. The anti-human class I antibody from protected monkeys would not be expected to down-regulate the activation of monkey T cells induced by
specific antigen by this route, because of the lack of cross-reactivity between the antibody and monkey class I antigens on monkey T cells. Since SIV antigen induced activation is at least 10X weaker than xenogenic or allogenic activation (Table 2), the T cell activation so induced may not be sufficient to support adequate virus replication to infect the monkeys. However, the antibody would be expected to strongly inhibit the activation of human T cells to specific antigens or itogens. This is indeed the case in experiments presented in Table 3. The finding suggests that anti-human HLA class I antibodies may be useful in immunotherapy against HIV infection.
Although our data suggest that the anti-class I antibody contributes towards the resistance to SIV infection in CD4* T lymphocytes, it may not have an effect on the infection of monocytes. In any case, the virus is not expected to replicate extensively in these cells, and virus grown in T cells or PHA activated PBMC would only infect the homologous cell type 3S.
EXAMPLE 2
Four macaques were vaccinated with a mixture of murine P815 cells transfected with HLA class I (B27) and purified HLA Al and B8 (the haplotype of C8166 cells) from a human B cell line as im unogen and using GMDP formulated with squalane and pluronic-in-water emulsion as adjuvant. Control monkeys were immunised with P815 cells and adjuvant. After the second vaccination, all 4 vaccinees showed good antibody response (>1/120) by flow cytometry on P815-B27 cells and on the human B cell line from which the HLA immunogen was prepared. Control animals had antibody titres of <l/30. After the third vaccination, the antibody titres in the vaccinees increased further to 1/1920 when assayed by flow cytometry on both P815-B27 and C8166 cells. The antibody titre in control animals remained at <l/30. Using radioimmunoassay with purified HLA I adsorbed to
plastic, the vaccinees had antibody titres of 1/120 - 1/480 whereas that of control animals and prebleeds was <l/30. Sera from the vaccinees but not the control animals were also shown to bind to the SIV virus envelope as demonstrated by immuno-gold labelling under electron microscopy.
REFERENCES
1. Stott, E.J. et al. Lancet 336, 1538-1541 (1990).
2. Stott, E.J. et al. Nature 353, 393 (1991).
3. Langlois, A.J. et al. Science 255, 292-293 (1992).
4. Le Grand. R. et al. Nature 355, 684 (1992).
5. Osterhaus, A., de Vries, P. and Heeney, J. Nature 355, 684-685 (1992).
6. Cranage, M.P., Ashworth, L.A.E., Greenaway, P.J., Murphey-Corb, M. and Desrosiers, R.C. Nature 355, 685-686
(1992).
7. Kitchin, P.A. et al. J. Virol. Methods 28, 85-100 (1990).
8. Chan, W.L. , Lukic, M.L. and Liew, F.Y. J. EX . Med. 162, 1304-1318 (1985).
9. McGrath, M. , Witte, O. , Pincus, T. and Weissan I.L. J. Virol. 25. 923-927 (1978).
10. LaThangue, N.B., Shriver, K. , Dawson, C. and Chan, W.L. EMBO J. 3, 267-277 (1984).
11. Sterkers, G. , Henin, Y., Kalil, J., Bagot, M. , and Levy, J- P. J. Iromun. 131, 2735-2740 (1983).
12. Chouaib, S., Welte, K. and Dupont, B. J. Immun. 134, 940-948 (1985).
13. Turco, M.C. et al. J. Immun. 135, 2268-2273 (1985).
14. Taylor, D.S., Nowell, P.C. and Kornbluth, J. Proc. Natl. Acad. Sci. 83. 4446-4450 (1986).
15. Spagnoli, G.C. et al. Scand. J. Iromuno1. 25, 555-565 (1987).
16. Huet, S. et al. Proc. Natl. Acad. Sci 84, 7222-7226 (1987) .
17. Dasgupta, J.D., Cemach, K. , Dubey, D.P., Yunis, E.J. and Amos, D.B. Proc. Natl. Acad. Sci. 84, 1094-1098 (1987).
18. Beckman, I., Xiaoning, X. and Bradley, J. Immunology 65,373-378 (1988).
19. Grassi, F. et al. J. Exp. Med. 174, 53-62 (1991).
20. Devaux, C. et al. Res. Immun. 141, 357-372 (1990).
21. Corbeau, P., Devaux, C. , Kourilsky, F. and Chermann,
J.C. J. Virol. 64, 1459-1464 (1990).
22. Corbeau, P., Olive, D. and Devaux, C. Eur. J. Immun. 21, 865-871 (1991).
23. Montefiori, D.C., Hirsch, V.M. and Johnson, P.R. Nature 354, 439-440 (1991).
24. Putkonen, P. et al. Nature 352, 436-438 (1991).
25. Maddox, J. Nature 353, 297 (1991).
26. Hui, S-L. , et al. Science 255, 456-459 (1992).
27. Henderson, L.E. et al. J. Virol. 61, 629-632 (1987).
28. McDougal J.S. et al. J. Immun. 135, 3151-3162 (1985).
29. Folks, T. et al. J. Immun. 136, 4049-4053 (1986).
30. Tong-Starksen, S.E., Luciw, P.A. and Peterlin B.M. J. Immun. 142, 702-707 (1989).
31. Gowda, S.J., Stein, B.S., Mohagheghpour, N. , Benike, C.J. and Engleman E.G. J. Immun. 142, 773-780 (1989).
32. Stevenson, M. , Stanwick, T.L. , Dempsey, M.P. and Lamonica, CA. EMBO J. 9, 1551-1560 (1990).
33. Mohagheghpour, N. , Chakrabar, R. , Stein B.S., Gowda, S.D. and Engleman, E.G. J. Biol. Chem. 266, 7233-7238 (1991) .
34. Bressler, P., Pantaleo, G. Demaria, A. and Fauci, A.S. J. Immun. 147. 2290-2294 (1991).
35. Meltzer, M.S. et al Immun. Today 11, 217-223 (1990).
36. Ribi, E. et al Clin. Immunol. Newsletter (5, 33-36, 1985
Claims (11)
1. A major histocompatibility complex class I antigen for use in a method of treatment of the human or animal body by therapy.
2. An antigen according to claim 1 for use as a vaccine against an immunodeficiency virus.
3. An antigen according to claim 2, wherein the virus is a human immunodeficiency virus(HIV) .
4. An antigen according to claim 3, wherein the virus is HIV-1.
5. An antigen according to claim 3, wherein the virus is HIV-2.
6. An antigen according to any one of the preceding claims, which is a human class I antigen.
7. An antigen according to claim 6, which is a HLA-A, HLA-B or HLA-C antigen or βz microglobulin.
8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, a major histocompatibility complex class I antigen.
9. Use of a major histocompatibility complex class I antigen in the manufacture of a medicament for use as a vaccine against an immunodeficiency virus.
10. A method of vaccinating a host against an immunodeficiency virus, which method comprises administering to the host an effective amount of a major histocompability complex class I antigen.
11. An agent useful as a vaccine against an immunodeficiency virus, which agent comprises a major histocompatibility class I antigen.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929214871A GB9214871D0 (en) | 1992-07-13 | 1992-07-13 | Vaccines |
GB9214871 | 1992-07-13 | ||
PCT/GB1993/001459 WO1994001130A1 (en) | 1992-07-13 | 1993-07-13 | A major histocompatibility complex antigen for use as vaccine against an immunodeficiency virus |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4576293A true AU4576293A (en) | 1994-01-31 |
Family
ID=10718631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU45762/93A Abandoned AU4576293A (en) | 1992-07-13 | 1993-07-13 | A major histocompatibility complex antigen for use as vaccine against an immunodeficiency virus |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0650369A1 (en) |
JP (1) | JPH07508984A (en) |
AU (1) | AU4576293A (en) |
CA (1) | CA2140150A1 (en) |
GB (1) | GB9214871D0 (en) |
WO (1) | WO1994001130A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1274592B (en) * | 1994-08-05 | 1997-07-18 | Angela Turiano | PHARMACEUTICAL COMPOSITION FOR CANCER THERAPY CONTAINING XENOANTIGENS |
FR2735984B1 (en) * | 1995-06-30 | 1997-09-19 | Inst Nat Sante Rech Med | VACCINE AGAINST INFECTIOUS AGENTS HAVING AN INTRACELLULAR PHASE, COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS, ANTIBODIES AND DIAGNOSTIC METHOD |
EP1000628A1 (en) * | 1998-09-28 | 2000-05-17 | Fondation Mondiale Recherche et Prevention SIDA | Use of antigenic complexes of HIV envelope and HLA class I antigens as HIV vaccine |
AU2005202644B2 (en) * | 1999-06-01 | 2009-03-05 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69124372T2 (en) * | 1990-05-10 | 1997-08-07 | Dana Farber Cancer Inst Inc | INCREASING THE ASSOCIATION OF EXOGENIC PEPTIDES WITH MHCI MOLECULES ON CELLS IN THE IMMUNE SYSTEM |
-
1992
- 1992-07-13 GB GB929214871A patent/GB9214871D0/en active Pending
-
1993
- 1993-07-13 WO PCT/GB1993/001459 patent/WO1994001130A1/en not_active Application Discontinuation
- 1993-07-13 AU AU45762/93A patent/AU4576293A/en not_active Abandoned
- 1993-07-13 CA CA002140150A patent/CA2140150A1/en not_active Abandoned
- 1993-07-13 JP JP6503132A patent/JPH07508984A/en not_active Withdrawn
- 1993-07-13 EP EP93916056A patent/EP0650369A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2140150A1 (en) | 1994-01-20 |
GB9214871D0 (en) | 1992-08-26 |
JPH07508984A (en) | 1995-10-05 |
WO1994001130A1 (en) | 1994-01-20 |
EP0650369A1 (en) | 1995-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chan et al. | Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. | |
Johnson et al. | Superantigens: structure and relevance to human disease | |
Putkonen et al. | Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys | |
EP0497883B1 (en) | Compositions and their use for promoting immunopotentiation | |
Yamamoto et al. | Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus | |
US6265539B1 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
US6406696B1 (en) | Methods of stimulating the immune system with anti-CD3 antibodies | |
Belshe et al. | Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection | |
Lifson et al. | Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins | |
US6093405A (en) | Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines | |
Ward et al. | Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin | |
GARDNER et al. | Passive immunization of rhesus macaques against SIV infection and disease | |
WO1998015658A1 (en) | Compositions and methods for treating viral infections | |
AU710626B2 (en) | Non-toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation process and pharmaceutical compositions comprising them | |
WO1990014835A1 (en) | Method to treat rheumatoid arthritis | |
Wahren et al. | Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160 | |
Mills et al. | Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28‐derived recombinant env and gag proteins | |
EP0762895B1 (en) | Synthetic vaccine for protection against human immunodeficiency virus infection | |
Gorse et al. | Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration | |
AU4576293A (en) | A major histocompatibility complex antigen for use as vaccine against an immunodeficiency virus | |
US5733550A (en) | Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with β-microglobulin | |
Polyanskaya et al. | Anti-major histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection | |
Stott | Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines | |
EP0328390B1 (en) | Peptide treatment of refractory infectious diseases | |
Taffs et al. | Protection in Simian Immunodeficiency Virus-vaccinated Monkeys Correlates with Anti-HLA Class I Antibody Response By Woon Ling Chan, Angela Rodgers, Robert D. Hancock |